Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

molnupiravir

- PMLiVE

Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

Veklury demonstrated a reduction in mortality and hospital readmission rates

- PMLiVE

Merck to acquire Prometheus Biosciences for almost $11bn

The deal includes the biotech’s lead candidate for ulcerative colitis and Crohn's disease

- PMLiVE

Moderna/Merck’s cancer vaccine shows promise in high-risk melanoma patients

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck and Proxygen partner in deal worth up to $2.5bn

The companies will identify molecular glue degraders against multiple therapeutic targets

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

It is estimated there will be around 66,000 new cases of uterine cancer in the US this year

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

WHO report highlights impact of COVID-19 pandemic on non-communicable diseases

These diseases were responsible for an estimated 40 million of all deaths globally in 2019

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

- PMLiVE

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

The disease develops in the lungs and accounts for 75% of all cancerous mesothelioma cases

- PMLiVE

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

There are no FDA approved vaccines for EBV, one of the most common human viruses

- PMLiVE

JCVI recommends spring COVID-19 booster for those at highest risk

Eligible individuals will be offered the booster around six months after their previous dose

- PMLiVE

FDA approves intramuscular administration of Merck’s MMRV vaccines

Until now, the vaccines have only been administered via subcutaneous injection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links